Clinical Applications of Neuroimaging in Psychiatric Disorders
2018; American Psychiatric Association; Volume: 175; Issue: 9 Linguagem: Inglês
10.1176/appi.ajp.2018.1750701
ISSN1535-7228
AutoresMichael B. First, Wayne C. Drevets, Cameron Carter, Daniel P. Dickstein, Lauren I. Kasoff, Kerri L. Kim, Jonathan McConathy, Scott L. Rauch, Ziad S. Saad, Jonathan Savitz, Karen E. Seymour, Yvette I. Sheline, Jon‐Kar Zubieta,
Tópico(s)Autism Spectrum Disorder Research
ResumoBack to table of contents Previous article Official ActionsFull AccessClinical Applications of Neuroimaging in Psychiatric DisordersMichael B. First, M.D., Wayne C. Drevets, M.D., Cameron Carter, M.D., Daniel P. Dickstein, M.D., Lauren Kasoff, B.S., Kerri L. Kim, Ph.D., Jonathan McConathy, M.D., Ph.D., Scott Rauch, M.D., Ziad S. Saad, Ph.D., Jonathan Savitz, Ph.D., Karen E. Seymour, Ph.D., Yvette I. Sheline, M.D., Jon-Kar Zubieta, M.D., Ph.D.Michael B. FirstSearch for more papers by this author, M.D., Wayne C. DrevetsSearch for more papers by this author, M.D., Cameron CarterSearch for more papers by this author, M.D., Daniel P. DicksteinSearch for more papers by this author, M.D., Lauren KasoffSearch for more papers by this author, B.S., Kerri L. KimSearch for more papers by this author, Ph.D., Jonathan McConathySearch for more papers by this author, M.D., Ph.D., Scott RauchSearch for more papers by this author, M.D., Ziad S. SaadSearch for more papers by this author, Ph.D., Jonathan SavitzSearch for more papers by this author, Ph.D., Karen E. SeymourSearch for more papers by this author, Ph.D., Yvette I. ShelineSearch for more papers by this author, M.D., Jon-Kar ZubietaSearch for more papers by this author, M.D., Ph.D.Published Online:1 Sep 2018https://doi.org/10.1176/appi.ajp.2018.1750701AboutSectionsView articleSupplemental MaterialPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail View articleIn response to claims being made that brain imaging technology had already reached the point at which it could be useful for making a clinical diagnosis and for helping in treatment selection in individual patients, the APA Assembly passed an action paper calling for the development of an APA Position Paper on the Clinical Application of Brain Imaging in Psychiatry. Consequently, a workgroup was appointed under the auspices of the APA Council on Research to develop an evidenced-based review of the current state of the art of the clinical utility of brain imaging for psychiatric diagnosis and for predicting treatment response. The review focused on the following diagnostic areas: adult mood and anxiety disorders, psychotic disorders, cognitive disorders, substance use disorders, and childhood disorders, including attention deficit hyperactivity disorder, childhood bipolar disorder, depression/anxiety, and autism spectrum disorder. This review was approved by the APA Board of Trustees as a resource document. The review is summarized below, and the full resource document is available in a data supplement accompanying the online version of this APA Official Action (ajp.psychiatryonline.org).In clinical medicine, there has been considerable interest in developing objective, biologically based tests for psychiatric disorders. Such advances could yield important benefits, such as predicting treatment response, differentiating between related diagnostic categories, and potentially treating at-risk patients prophylactically to prevent neurotoxicity and clinical deterioration. For over two decades, brain imaging has maintained a well-established but narrow place in the diagnostic evaluation of patients with psychiatric disorders, largely because of the usefulness of neuromorphological MRI in detecting and characterizing structural brain abnormalities, such as lesions and atrophy.The successful application of neuroimaging technology in psychiatric research has revolutionized clinical neuroscience perspectives on the pathophysiology of the major psychiatric disorders. Yet despite the invaluable leads that the neuroimaging studies have provided regarding the neurobiological bases for psychiatric disorders, except in the case of neurocognitive disorders, neuroimaging has yet to have a significant impact on the diagnosis or treatment of individual patients in clinical settings. This is largely due to the fact that the effect size of neuroimaging and other biological abnormalities identified to date for most psychiatric disorders has been relatively small, and thus imaging measures do not provide sufficient specificity and sensitivity to accurately classify individual cases with respect to the presence of a psychiatric illness.Suggested standards for the development of clinically useful diagnostic biomarkers (adapted from the 1998 Consensus Report of the Working Group on Molecular and Biochemical Markers of Alzheimer’s Disease) include the following: 1) the biomarker should have a sensitivity of at least 80% for detecting a particular psychiatric disorder and a specificity of at least 80% for distinguishing this disorder from other psychiatric or medical disorders; 2) the biomarker should be reliable, reproducible, and ideally be noninvasive, simple to perform, and inexpensive; and 3) data used to validate the biomarker should be confirmed by at least two independent sets of qualified investigators in independent study samples, with the results published in peer-reviewed journals.According to this standard, the psychiatric imaging literature currently does not support the application of a diagnostic biomarker to positively establish the presence of any primary psychiatric disorder. This is in contrast to amyloid positron emission tomography scans, in which reduced binding in gray matter can be used to exclude the diagnosis of Alzheimer’s disease. Although assessments of intrarater and interrater reliabilities commonly are reported for quantitative neuroimaging measures, these have been limited to establishing measurement reliability (e.g., of cerebral volumes or neuroreceptor binding potential) but not to the reliability of diagnostic interpretation. Thus, the peer-reviewed scientific literature, except in the case of neurocognitive disorders, does not yet contain a single example of a diagnostic imaging biomarker with regard to a psychiatric disorder or treatment for which relatively high intra- and interrater reliabilities have been reported in two independent studies. Similarly, except in the case of neurocognitive disorders, there is not yet a case in the literature in which neuroimaging measures obtained from the same region(s) of interest have shown both a sensitivity >80% for detecting a particular psychiatric disorder and a specificity >80% for distinguishing this disorder from healthy control subjects or other relevant psychiatric disorders in at least two independent studies.In summary, considerable effort is currently being invested in using modern statistical and computational tools to utilize structural and functional MRI for diagnostic purposes in patients with a wide range of psychiatric diagnoses. This approach has yielded some promising results but also methodological caution that seems largely addressable as more rigorous studies are performed on a much larger scale than has been typical to date. While there is reason to be hopeful that these methods will eventually yield generalizable and replicable results that will permit their application in clinical practice, at this time, the majority of neuroimaging’s utility remains as a research tool only. FiguresReferencesCited byDetailsCited byBeyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders10 May 2022 | Journal of Neurochemistry, Vol. 164, No. 37T ultra-high-field neuroimaging for mental health: an emerging tool for precision psychiatry?26 January 2022 | Translational Psychiatry, Vol. 12, No. 1Studying Mental Health Problems as Systems, Not Syndromes6 October 2022 | Current Directions in Psychological Science, Vol. 31, No. 6Effects of Antipsychotic Medications and Illness Duration on Brain Features That Distinguish Schizophrenia Patients4 August 2022 | Schizophrenia Bulletin, Vol. 48, No. 6Spatiotemporal Precision of Neuroimaging in PsychiatryBiological Psychiatry, Vol. 17Editorial: The Emerging Role of SPECT Functional Neuroimaging in Psychiatry & Neurology4 July 2022 | Frontiers in Psychiatry, Vol. 13TELOMERE LENGTH AS A MARKER OF SUICIDAL RISK IN SCHIZOPHRENIA21 June 2022 | Consortium PsychiatricumMinimum spanning tree analysis of brain networks: A systematic review of network size effects, sensitivity for neuropsychiatric pathology, and disorder specificity1 June 2022 | Network Neuroscience, Vol. 6, No. 2The Legacy of the TTASAAN Report – Premature Conclusions and Forgotten Promises About SPECT Neuroimaging: A Review of Policy and Practice Part II17 May 2022 | Frontiers in Neurology, Vol. 13Increased Asymmetric Perfusion of the Cerebral Cortices and Thalamus Indicates Individuals at Risk for Bipolar Disorder: A Family Cohort Single Photon Emission Computed Tomography Neuroimaging Study10 May 2022 | Frontiers in Psychiatry, Vol. 13The Legacy of the TTASAAN Report—Premature Conclusions and Forgotten Promises: A Review of Policy and Practice Part I28 March 2022 | Frontiers in Neurology, Vol. 12Clinical translational neuroimaging of the antioxidant effect of N ‐acetylcysteine on neural microstructure30 September 2021 | Magnetic Resonance in Medicine, Vol. 87, No. 2A New Way Forward: How Brain SPECT Imaging Can Improve Outcomes and Transform Mental Health Care Into Brain Health Care10 December 2021 | Frontiers in Psychiatry, Vol. 12Cost-effectiveness of neuroimaging technologies in management of psychiatric and insomnia disorders: A meta-analysis and prospective cost analysisJournal of Neuroradiology, Vol. 48, No. 5Clinical use of neuro-imaging in psychiatric patients at the Charlotte Maxeke Johannesburg Academic Hospital28 May 2021 | South African Journal of Psychiatry, Vol. 27Bridging the Gap: Strategies to Make Psychiatric Neuroimaging Clinically Relevant22 April 2021 | Harvard Review of Psychiatry, Vol. 29, No. 3Core Values, Technologies, Neuroscience, and Law/Policy: Next Big Things for Emotional and Behavioral DisordersNeuroimaging in attention-deficit/hyperactivity disorder15 January 2021 | Current Opinion in Psychiatry, Vol. 34, No. 2Systematic Review: Medication Effects on Brain Intrinsic Functional Connectivity in Patients With Attention-Deficit/Hyperactivity DisorderJournal of the American Academy of Child & Adolescent Psychiatry, Vol. 60, No. 2Precision Medicine and a Learning Health System for Mental Health19 November 2021How brain single photon emission computed topography imaging informs the diagnosis and treatment of mood disordersIndividual prediction of trauma-focused psychotherapy response in youth with posttraumatic stress disorder using resting-state functional connectivityNeuroImage: Clinical, Vol. 32An imaging-based risk calculator for prediction of conversion to psychosis in clinical high-risk individuals using glutamate 1H MRSSchizophrenia Research, Vol. 226A Reckoning to Keep Doing What We Are Already Doing With PET and SPECT Functional NeuroimagingTheodore A. Henderson, M.D., Ph.D., Philip Cohen, M.D., F.R.C.P.C., Muriel van Lierop, M.B.B.S., M.D.P.A.C.(M.), John Thornton, M.B., F.R.C.P.C., Mary K. McLean, M.B., Ch.B., John Michael Uszler, M.D., M.S., Yin-Hui Siow, M.D., F.R.C.P.C., Giuseppe Cardaci, M.B.B.S., F.R.A.C.P.1 July 2020 | American Journal of Psychiatry, Vol. 177, No. 7A Reckoning and Research Agenda for Neuroimaging in Psychiatry: Response to Henderson et al.Amit Etkin, M.D., Ph.D.1 July 2020 | American Journal of Psychiatry, Vol. 177, No. 7Your evidence? Machine learning algorithms for medical diagnosis and predictionHuman Brain Mapping, Vol. 41, No. 6Functional Neuroimaging in Psychiatry—Aiding in Diagnosis and Guiding Treatment. What the American Psychiatric Association Does Not Know15 April 2020 | Frontiers in Psychiatry, Vol. 11 Volume 175Issue 9 September 01, 2018Pages 915-916 Metrics PDF download History Published online 1 September 2018 Published in print 1 September 2018
Referência(s)